CClinicalTrials.gg
CompletedNCT00233259Updated Oct 25, 2011

Lifestyle Modification Program to Reduce Risk of Coronary Heart Disease in Latina Women With Diabetes

An interventional study of Mediterranean Diet and Physical Activity in Cardiovascular Diseases, Heart Diseases and Diabetes Mellitus, Type 2, sponsored by Oregon Research Institute. Completed at 1 site in United States. Open to female participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-10-25.

Sponsored by Oregon Research Institute · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
273
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
Female
01

Study summary

The Viva Bien! trial will comprehensively evaluate a multiple risk factor intervention (diet, physical activity, stress management, social support, and smoking cessation) in a randomized effectiveness trial, which will be offered in English and Spanish to diabetic Latinas.

Read the detailed description

BACKGROUND:

Age-adjusted mortality from coronary heart disease (CHD) has been increasing in women with diabetes. On the other hand, it has been decreasing in women without diabetes and in men with and without diabetes. CHD remains the leading cause of death among women in the United States. Risks of CHD and resulting death are significantly higher among postmenopausal women; these rates are two and a half times higher among women with diabetes versus women without diabetes. Diabetes is an independent risk factor for CHD in both Latina and Anglo women, but it appears to be a greater risk factor for U.S. born Latinas, as they have higher mortality from diabetes. Among Latinas, diabetes ranks as the third leading cause of death.

DESIGN NARRATIVE:

Hispanic Americans, in particular postmenopausal Hispanic women, have an increased prevalence of type 2 diabetes, and a greater incidence of diabetes complications than non-Hispanic whites. The LLP will comprehensively evaluate a multiple risk factor intervention (diet, physical activity, stress management, social support, and smoking cessation) in a randomized effectiveness trial that will be offered in English and Spanish. The research team has shown that a similar theory-based comprehensive program, Mediterranean Lifestyle Program (MLP), is effective in improving behavioral, psychosocial, quality of life, and physiologic outcomes in postmenopausal Anglo women with type 2 diabetes. Though the results are promising, four important research issues must be addressed before such a program is ready to be put into practice. This study focuses on the following questions: 1) How should the structure and content of the MLP be modified to address the cultural characteristics of Latinas?; 2) Will the program succeed if offered within a large health plan that serves minority populations (i.e., the Kaiser Permanente site in Denver, CO)?; and 3) What are the economic implications of the LLP? The Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) evaluation framework will be used to assess how the program impacts certain dimensions that are important for carry over into clinical practice. Primary outcomes of this study will include change in behavioral measures. Secondary outcomes will include impacts on quality of life, physiologic measures, member satisfaction, and cost-effectiveness. The investigators will also study the relationship between cultural variables in this Hispanic population (e.g., family and social support; group cohesion; and acculturation) and program participation and outcomes. Substantial impacts of this study on public health include: 1) intervening with a high-risk, underserved population; 2) focusing on multiple critically important lifestyle behaviors known to reduce risk for CHD; 3) testing maintenance of behavioral changes; 4) employing methodology to estimate the program's readiness to be put into practice; and (5) measuring the robustness, reach, and cost-effectiveness of the program.

02

Conditions studied

  • Cardiovascular Diseases
  • Heart Diseases
  • Diabetes Mellitus, Type 2
03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

This study's enrollment of 273 is above the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Oregon Research Institute is the lead sponsor of 70 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Type 2 diabetes
  • Postmenopausal
  • Latina

Exclusion criteria

Exclusion criteria:

  • Cognitive impairment or inability to comprehend program
  • Has other life-threatening illnesses
  • Planning to move from the area during the study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
273 participants (actual)

Study arms

  • Active comparator
    1

    Multiple risk factor intervention, that will include diet, physical activity, stress management, social support, and smoking cessation components

    Behavioral: Mediterranean Diet · Behavioral: Physical Activity · Behavioral: Stress Management · Behavioral: Social Support · Behavioral: Smoking Cessation

  • Placebo comparator
    2

    Control group

    Other: Control group

Interventions

  • BehavioralMediterranean Diet

    Mediterranean dietary program

  • BehavioralPhysical Activity

    Physical activity program

  • BehavioralStress Management

    Stress management program

  • BehavioralSocial Support

    Social support

  • BehavioralSmoking Cessation

    Smoking cessation program

  • OtherControl group

    Usual Diabetes Care Control group

06

What researchers measure

Primary outcomes

  1. Adherence to the Mediterranean Diet, physical activity, stress management, and smoking cessation protocols

    Time frame: Measured at baseline, 6, 12, and 24 months

  2. Hemoglobin A1c

    Time frame: Measured at baseline, 6, 12, and 24 months

Secondary outcomes

  1. Social support

    Time frame: Measured at baseline, 6, 12, and 24 months

07

Study locations

1 site
  • Institute for Health Research
    Denver, Colorado 80237, United States
08

References and documents

Publications

  • Toobert DJ, Strycker LA, King DK, Barrera M Jr, Osuna D, Glasgow RE. Long-term outcomes from a multiple-risk-factor diabetes trial for Latinas: inverted exclamation markViva Bien! Transl Behav Med. 2011 Sep;1(3):416-426. doi: 10.1007/s13142-010-0011-1. PubMed 22022345 ↗
  • Toobert DJ, Strycker LA, Glasgow RE, Osuna D, Doty AT, Barrera M, Geno CR, Ritzwoller DP. Viva bien!: Overcoming recruitment challenges in a multiple-risk-factor diabetes trial. Am J Health Behav. 2010 Jul-Aug;34(4):432-41. doi: 10.5993/ajhb.34.4.5. PubMed 20218755 ↗
  • Osuna D, Barrera M Jr, Strycker LA, Toobert DJ, Glasgow RE, Geno CR, Almeida F, Perdomo M, King D, Doty AT. Methods for the cultural adaptation of a diabetes lifestyle intervention for Latinas: an illustrative project. Health Promot Pract. 2011 May;12(3):341-8. doi: 10.1177/1524839909343279. Epub 2009 Oct 20. PubMed 19843703 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00233259
Lead sponsor
Oregon Research Institute
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Sponsor
First posted
Oct 5, 2005
Start date
Mar 2006
Primary completion
Aug 2010
Completion
Aug 2010
Last update
Oct 25, 2011

Study contacts

Deborah J. Toobert, PhD
study chair · Oregon Research Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion